Orforglipron
Also known as: Foundayo, LY3502970, OWL833, OWL-833
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved (as Foundayo, April 2026) for chronic weight management. It works through the same GLP-1 satiety and glycemic pathways as injectable semaglutide (appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion) not anabolic pathways, and does not affect testosterone or muscle building. Rated 3, matching other approved GLP-1 weight agents; its significance is the oral small-molecule format and manufacturing scalability, not a more aggressive physiological effect.
Overview
An oral, non-peptide (small-molecule) GLP-1 receptor agonist from Eli Lilly, FDA-approved in April 2026 under the brand name Foundayo. Unlike peptide GLP-1 drugs, which must be injected or taken as a highly restricted oral tablet, orforglipron is a chemically stable small molecule that can be taken once daily as a pill with no food restrictions. In the ATTAIN-1 Phase 3 obesity trial the highest dose (36mg) produced -11.2% mean weight loss at 72 weeks (treatment-regimen estimand) versus -2.1% for placebo. The big deal is the format: an easy-to-manufacture oral GLP-1 with the potential to scale globally.
Important Warnings
- •Boxed warning: risk of thyroid C-cell tumors observed in rodent studies; contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
- •Rapid weight loss causes lean-mass (muscle) loss unless protein and resistance training are prioritized
- •GI-related discontinuation occurs in ~5-10% of users across the ATTAIN-1 and ACHIEVE-1 trials, titrate slowly
- •Not recommended in patients with severe gastroparesis
- •Rebound weight gain is common after discontinuation without sustained lifestyle change
- •Do not stack with injectable GLP-1/GIP agonists, additive GI and dehydration risk
Purpose & Use Cases
Weight Loss
ATTAIN-1 (obesity, no diabetes, n=3,127) showed dose-dependent weight loss at 72 weeks: -7.5% (6mg), -8.4% (12mg) and -11.2% (36mg) mean body weight change (treatment-regimen estimand) vs -2.1% for placebo. At the 36mg dose, ~54.6% of participants lost at least 10% and ~36.0% lost at least 15% of body weight.
Oral GLP-1 Convenience
A once-daily pill taken with or without food: a major adherence and access advantage over injectables and over the more restrictive oral peptide (Rybelsus) format, which requires an empty stomach and a water-only window.
Type 2 Diabetes / Glycemic Control
The ACHIEVE-1 trial (early type 2 diabetes, n=559, 40 weeks) showed HbA1c reduction of up to -1.48 percentage points and ~7.6% weight loss at the 36mg dose, versus -0.41 points and -1.7% for placebo.
Benefits
- Oral once-daily dosing with no food restrictions
- Non-peptide small molecule: scalable manufacturing and no cold-chain/injection burden
- Meaningful weight loss (~11% at the highest trial dose) and glycemic improvement
- Safety profile broadly consistent with injectable GLP-1 medicines
- First oral GLP-1 FDA-approved specifically for chronic weight management (Foundayo, April 2026)
Good to Know
The big deal is that it is ORAL and non-peptide
Orforglipron is a small molecule, not a peptide, so it survives stomach acid, is not chewed up by DPP-4, and needs no absorption enhancers or fasting window. It is a once-a-day pill you can take with or without food, a genuine access and adherence breakthrough versus injections and the more restrictive Rybelsus tablet.
Effective, but trails the top injectables
At -11.2% mean weight loss (36mg, ATTAIN-1, 72 weeks) it is meaningful but below injectable tirzepatide (~20-23%) and retatrutide (~24%). The trade-off is convenience and scalable manufacturing, not maximum efficacy.
Same GLP-1 side effects, oral route
Being a pill does not remove the GI profile. Nausea, diarrhea, vomiting and dose-driven discontinuation are all present. Slow titration still matters.
Lean-mass loss during rapid weight loss
Like all GLP-1 agents, weight lost includes muscle if protein and training lapse. High protein plus resistance training shifts the fat-to-lean loss ratio, important in a physique context.
No anabolic or hormonal action
Does not raise or suppress testosterone, does not aromatize, no HPTA effect. No AI and no PCT considerations: it is a metabolic/appetite tool.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.8 – 2.5 mg/day |
| Intermediate | 5.5 – 9 mg/day |
| Advanced | 14.5 – 17.2 mg/day |
FDA-approved (Foundayo) commercial titration: start at 0.8mg/day for at least 30 days, then 2.5mg for at least 30 more days, then 5.5mg; from there, doses may be increased at 30-day intervals to 9mg, 14.5mg or a maximum of 17.2mg/day based on tolerability and response. The 0.8mg and 2.5mg doses are sub-therapeutic initiation steps, not maintenance targets. This approved commercial schedule uses different mg strengths than the pivotal ATTAIN-1/ACHIEVE-1 trials, which tested 3mg/6mg/12mg/36mg dose arms of an earlier trial formulation. The numbers are not directly comparable across trial and commercial tablets. Missing 7 or more consecutive daily doses requires restarting titration at a lower dose.
Per the FDA label; this ~29-49 hour half-life supports once-daily oral dosing.
Side Effects
Nausea
very commonThe most common side effect, from GLP-1-driven delayed gastric emptying; FDA label lists an incidence of ~26-35%, typically mild-to-moderate and worst during titration.
Slow titration; smaller meals; avoid fatty foods.
Constipation
very commonSlowed GI motility; FDA label lists an incidence of ~20-27%.
Fiber, hydration, movement.
Diarrhea
very commonCommon GI disturbance, usually during dose escalation; FDA label lists an incidence of ~21-25%.
Stay hydrated; slow titration.
Vomiting
very commonOccurs particularly at higher doses or with rapid titration; FDA label lists an incidence of ~13-24%.
Slow titration; do not overeat.
Dyspepsia
very commonUpper-abdominal discomfort/indigestion; FDA label lists an incidence of ~12-16%.
Smaller meals; avoid fatty or spicy foods; slow titration.
GI-Related Discontinuation
uncommonIn ATTAIN-1, 5.3-10.3% of orforglipron recipients discontinued due to adverse events (vs 2.7% placebo); in ACHIEVE-1 (diabetes), 4.4-7.8% discontinued due to adverse events (vs 1.4% placebo), predominantly gastrointestinal.
Slower titration and staying at a tolerated dose reduces dropout.
Acute Pancreatitis
rareRare but serious, class-wide GLP-1 risk; FDA label lists an incidence of ~0.14 per 100 patient-years.
Discontinue immediately and seek medical care for severe, persistent abdominal pain. Not studied in patients with a history of pancreatitis.
General Mitigation Strategies
GI side effects are dose-dependent and improve with continued use; a slow, patient titration is the main mitigation and reduces the discontinuation risk. Stay hydrated. As with any rapid weight-loss agent, keep protein high and train with resistance to protect lean mass. Discontinue and seek care for severe persistent abdominal pain (pancreatitis concern).
Support Supplements
Ancillary supplements commonly run alongside Orforglipron to manage side effects, support the target tissue, or fill nutrient demands it creates.
High Protein Intake
KeyAppetite suppression makes it easy to under-eat protein, accelerating lean-mass loss. Adequate protein is the primary lever for preserving muscle during weight loss.
- Dose
- 1.6-2.2 g per kg bodyweight per day
- Timing
- Spread across meals; prioritize protein when appetite is low
Resistance Training
KeyThe essential stimulus for retaining lean mass in a caloric deficit; without it a larger share of lost weight is muscle. A companion protocol, not a supplement.
- Timing
- 2-4 sessions per week, progressive overload
Creatine Monohydrate
Supports strength and lean-mass retention during a deficit; cheap and well-evidenced.
- Dose
- 3-5 g daily
- Timing
- Any time, daily and consistent
Electrolytes & Fiber
Reduced intake lowers electrolytes and fiber; supports GI comfort, hydration and constipation prevention.
- Dose
- Sodium/potassium/magnesium to appetite; 25-35 g fiber/day
- Timing
- Daily
Post Cycle Therapy (PCT)
Not anabolic-hormonal. Does not affect the HPTA. No PCT required. Weight regain is common after stopping without sustained habits.
How It Works
Orforglipron is a small-molecule agonist of the GLP-1 receptor. It activates GLP-1 signaling to suppress appetite, slow gastric emptying, stimulate glucose-dependent insulin secretion and reduce glucagon, the same downstream effects as peptide GLP-1 agonists like semaglutide. It is a partial agonist biased toward G-protein signaling over beta-arrestin recruitment. Being a small molecule, it is stable in stomach acid and is not degraded by peptidases such as DPP-4, so it is absorbed efficiently without the absorption enhancers, fasting windows and water restrictions that oral peptide GLP-1s require. Its half-life supports once-daily dosing at any time of day.
Fundamentals
Reference on the practices relevant to Orforglipron: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
FDA-approved prescription medication (brand name Foundayo, approved April 2026) for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside diet and exercise.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Orforglipron (Foundayo) is not listed on the WADA Prohibited List. Like the FDA-approved GLP-1s semaglutide and tirzepatide, it is a legitimate prescription medicine for weight/glycemic management rather than a banned substance; verify current status before competition as GLP-1-class scrutiny is an evolving area.